Access Equity Research

News

Virtual & In-person Roadshows / Conferences

Channelchek Premium. Access more at no cost. 

The site "channelcheck" is opened on the phone

Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost. 

Access to Exclusive Content. FREE for Registered Users Only. 

Click “Log In” to agree to Channelchek.com <a href="#">Terms of Use</a> and acknowledge that Channelchek.com <a href="#">Privacy Policy</a> applies to you.

Welcome to the Channelchek Investor Community

Informed investors make more money. And it’s all about timing. Get it when it happens.

Inbox Intel from Channelchek.

<figure class="wp-block-image aligncenter size-full"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/lode-logo-pr.png" alt="" class="wp-image-49690"/></figure>



<a href="http://www.channelchek.com/company/lode">Research News and Market Data on LODE </a>



VIRGINIA CITY, Nev., January 09, 2026 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) and Comstock Metals LLC (“Comstock Metals”), a leader in the responsible recycling of end-of-life solar panels with the only certified, North American, zero-landfill solution, announced today that it has received its Written Determination Permit from the Nevada Division of Environmental Protection – Bureau of Sustainable Materials Management (NDEP-BSMM), for the processing of waste solar panels and photovoltaics for its industry-scale materials recovery facility located in Silver Springs, NV. This timely and final required approval results in a fully permitted operation and facility and keeps our scale up plans for commissioning this industry-first, large scale processing facility in Silver Springs, NV, right on schedule.



On January 5, 2026, Comstock Metals received a similar notification of approval for the associated Air Quality control permit. These last two permits, represent the complete scope of required regulatory approvals for commissioning the scale up of a facility designed for processing more than 3 million panels per year from one, continuous production line, representing up to 100,000 tons per year of waste materials being processed. This facility integrates technologies for efficiently crushing, conditioning, extracting, and recycling metal concentrates from photovoltaics. The Company previously ordered all of the equipment and &nbsp;received deliveries during Q4 2025 and remains on schedule for receiving the rest of the equipment, installing, testing, and commissioning this first of its kind industry-scale facility during the first quarter of 2026.



“We appreciate BSMM’s collaborative engagement in issuing the first industry-scale Written Determination permit for solar panel recycling, a key regulatory milestone that enables Nevada’s only zero-landfill, high-volume, end-of-life solar panel recycling solution serving the broader region,” said Dr. Fortunato Villamagna, President of Comstock Metals. “This authorization aligns with our original permitting timeline and reflects the effectiveness of our regulatory strategy, the strength of our relationships with regulators, and the successful execution of a complex, first-of-its-kind permitting process.”



Many of the U.S. solar panels have been deployed in the southwestern U.S., primarily California, Arizona, and Nevada, with decommissioning of these solar panels occurring now, accelerating supply and increasing the demand for environmentally responsible end-of-life solutions. Comstock has positioned itself to ensure the safe deconstruction and productive reuse of these important materials. Establishing our platform in Nevada establishes the leading solar recycling position over more than half the U.S. market for end-of-life panels and establishes a platform for rapid expansion across the rest of the United States.



“Comstock Metals is setting the global standard in solar panel recycling by creating a scalable, reliable, efficient, and optimized network of decommissioning, collecting, aggregating, storing and full-recovery processing (and ultimately refining) nodes designed and built for speed and scale,” said Corrado De Gasperis, Executive Chairman and CEO of Comstock. “Most of the industry is still getting their heads around the magnitude of inevitable end of life panel dilemma, measured in the billions of panels, while we deploy and deliver a full end of life solution.”



About Comstock Inc.



Comstock Inc. (NYSE: LODE) innovates and commercializes technologies, systems and supply chains that enable, support and sustain clean energy systems by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable metals, like silver, aluminum, gold, and other critical minerals, primarily from end-of-life photovoltaics. To learn more, please visit&nbsp;<a href="http://www.comstock.inc/">www.comstock.inc</a>.



Comstock Social Media Policy



Comstock Inc. has used, and intends to continue using, its&nbsp;<a href="https://comstock.inc/investors/">investor relations</a>&nbsp;link and main website at&nbsp;<a href="http://www.comstock.inc/">www.comstock.inc</a>&nbsp;in addition to its&nbsp;<a href="https://x.com/comstockinc" target="_blank" rel="noreferrer noopener">X.com</a>,&nbsp;<a href="https://www.linkedin.com/company/comstock/" target="_blank" rel="noreferrer noopener">LinkedIn</a>&nbsp;and&nbsp;<a href="https://www.youtube.com/@comstockinc" target="_blank" rel="noreferrer noopener">YouTube</a>&nbsp;accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.



Contacts



For investor inquiries: Judd B. Merrill, Chief Financial Officer Tel (775) 413-6222 <a href="mailto:ir@comstockinc.com">ir@comstockinc.com</a>



For media inquiries: Zach Spencer, Director of External Relations Tel (775) 847-7573 <a href="mailto:media@comstockinc.com">media@comstockinc.com</a>



Forward-Looking Statements&nbsp;



This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; divestitures, spin-offs or similar distribution transactions, future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, divestitures, spin-offs or similar distribution transactions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, spin-offs or similar distribution transactions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

Research News and Market Data on LODE 



VIRGINIA CITY, Nev., January 09, 2026 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) and Comstock Metals LLC (“Comstock Metals”), a leader in the responsible recycling of end-of-life solar panels with the only certified, North American, zero-landfill solution, announced today that it has received its Written Determination Permit from the Nevada Division of Environmental Protection – Bureau of Sustainable Materials Management (NDEP-BSMM), for the processing of waste solar panels and photovoltaics for its industry-scale materials recovery facility located in Silver Springs, NV. This timely and final required approval results in a fully permitted operation and facility and keeps our scale up plans for commissioning this industry-first, large scale processing facility in Silver Springs, NV, right on schedule.



On January 5, 2026, Comstock Metals received a similar notification of approval for the associated Air Quality control permit. These last two permits, represent the complete scope of required regulatory approvals for commissioning the scale up of a facility designed for processing more than 3 million panels per year from one, continuous production line, representing up to 100,000 tons per year of waste materials being processed. This facility integrates technologies for efficiently crushing, conditioning, extracting, and recycling metal concentrates from photovoltaics. The Company previously ordered all of the equipment and &nbsp;received deliveries during Q4 2025 and remains on schedule for receiving the rest of the equipment, installing, testing, and commissioning this first of its kind industry-scale facility during the first quarter of 2026.



“We appreciate BSMM’s collaborative engagement in issuing the first industry-scale Written Determination permit for solar panel recycling, a key regulatory milestone that enables Nevada’s only zero-landfill, high-volume, end-of-life solar panel recycling solution serving the broader region,” said Dr. Fortunato Villamagna, President of Comstock Metals. “This authorization aligns with our original permitting timeline and reflects the effectiveness of our regulatory strategy, the strength of our relationships with regulators, and the successful execution of a complex, first-of-its-kind permitting process.”



Many of the U.S. solar panels have been deployed in the southwestern U.S., primarily California, Arizona, and Nevada, with decommissioning of these solar panels occurring now, accelerating supply and increasing the demand for environmentally responsible end-of-life solutions. Comstock has positioned itself to ensure the safe deconstruction and productive reuse of these important materials. Establishing our platform in Nevada establishes the leading solar recycling position over more than half the U.S. market for end-of-life panels and establishes a platform for rapid expansion across the rest of the United States.



“Comstock Metals is setting the global standard in solar panel recycling by creating a scalable, reliable, efficient, and optimized network of decommissioning, collecting, aggregating, storing and full-recovery processing (and ultimately refining) nodes designed and built for speed and scale,” said Corrado De Gasperis, Executive Chairman and CEO of Comstock. “Most of the industry is still getting their heads around the magnitude of inevitable end of life panel dilemma, measured in the billions of panels, while we deploy and deliver a full end of life solution.”



About Comstock Inc.



Comstock Inc. (NYSE: LODE) innovates and commercializes technologies, systems and supply chains that enable, support and sustain clean energy systems by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable metals, like silver, aluminum, gold, and other critical minerals, primarily from end-of-life photovoltaics. To learn more, please visit&nbsp;www.comstock.inc.



Comstock Social Media Policy



Comstock Inc. has used, and intends to continue using, its&nbsp;investor relations&nbsp;link and main website at&nbsp;www.comstock.inc&nbsp;in addition to its&nbsp;X.com,&nbsp;LinkedIn&nbsp;and&nbsp;YouTube&nbsp;accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.



Contacts



For investor inquiries:Judd B. Merrill, Chief Financial OfficerTel (775) 413-6222ir@comstockinc.com



For media inquiries:Zach Spencer, Director of External RelationsTel (775) 847-7573media@comstockinc.com



Forward-Looking Statements&nbsp;



This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; divestitures, spin-offs or similar distribution transactions, future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, divestitures, spin-offs or similar distribution transactions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, spin-offs or similar distribution transactions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

Release - Comstock Metals Completes All Permits for First of Its Kind Recycling Facility

Comstock Inc.

LODE

Natural Resources

<figure class="wp-block-image aligncenter size-large is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2023/08/toi_logo.png-1024x1024.png" alt="" class="wp-image-95832" style="width:167px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/toi">Research News and Market Data on TOI</a>



Jan 09, 2026



<a href="https://investors.theoncologyinstitute.com/node/10401/pdf" target="_blank" rel="noreferrer noopener">PDF Version</a>



Rakesh Panda appointed Chief Information Officer



Nolan Mariano appointed Chief People Officer



CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) announced today the promotions of&nbsp;Rakesh Panda&nbsp;to Chief Information Officer and&nbsp;Nolan Mariano&nbsp;to Chief People Officer. These promotions reinforce TOI’s continued focus on leading the way in value-based cancer care through further development of our technology-enabled care delivery platform as well as strengthening our mission-oriented culture supported by strong leadership.



Rakesh Panda has more than 25 years of experience across IT, digital transformation, cybersecurity, and enterprise software development, including leadership roles at Cisco and Infosys. Mr. Panda will continue to guide TOI’s technology strategy, including AI-enablement efforts and enterprise-level data privacy and security practices. Nolan Mariano has 18 years of experience in People Operations and organizational leadership across several industries. Mr. Mariano joined TOI in 2022 and, as Chief People Officer, will oversee HR Operations, Total Rewards, Learning and Development, and Talent Acquisition functions.



Dr. Daniel Virnich, Chief Executive Officer at TOI, commented, “I'm extremely pleased to promote two strong internal leaders into key roles at TOI as we continue to experience rapid growth and new ways of driving world-class community-based cancer care for our patients and payor partners.”



About The Oncology Institute



Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.



Contacts



Media



The Oncology Institute, Inc. <a href="https://www.globenewswire.com/Tracker?data=Xjl1IciNXXWF4KfJGxRLsYYPT07NkJbxdwuFDImmdTXS-WR4cEaM2mj0XyThlo2dWP_4HVxZ7djMOBuBRbCAIrsb5yKBUcLsaHsfLiovtwhmaK_cAKBKERVjGH_67-ek7aPb-S3km3N7-xQbh_Q5_RbJk4aQxTghw8VpJqAfMQbOmgWQd-SfcF7upLUkkpY9-Mq4l6VGi4g4FjFROzkAAieMq_D8YSW2ZZjaYySDUYSE1U2-Qwu0aktDTSUinrp0EkQ6rE4tJoENxDxI2F_J_YdzhBl_G3j38RYxItlbP-gBfiTNIauNggPUIOfgYGI4YlNwbYrHDTv3D6sUGIW6-b2-TNLgFz_rq6JuEv4kscqU6ovvXgSL2tivYRIUJYcVlkxy2jajXLTKQ5mNnu4QUJx4s2IuQloPhJ0nfWPWwZ0UZDa4L_hsupOh8Yx0AanQN7TrSvApHEOVCpMv54-OTOER7ad52fKNwymaQeiBRZEhKR4oGdY3Y9vTnXHzhVikFCY09ypwyrOSSt7BFA-8sHZv-ViWJJloCIxnH2Z29VvD3mfq1NlXB78heR7mrPsug8Eu0T8owfbcVkB3E-kbmiDC7UAwSy5IZOI909UDfhAbm0SW01fM-cwYRKN_VY2k8TMgHigTMJ-kXBXa50PtcSUh62VbczPFbR_dB4-8wTi_sreF4CwtKKhg5Z-gNkI5Mq1AWXF0w6ipQWsuenYUjYNmi-MOJ3POJaKJ0vEZiER0gK-Qk8KXDaEAUHc1wbtcMWcJKE0RWFogJYWkqpJcZ-qoM3ScFe7nq9qaEqc2jixc7dEdow778c3SXB5XEfvBQWb_QSayLzof2c35jicQ9G1cZv1i9_f51ByJiEGnc-tsbAU5N2lgVQPfu-nkutqIBUaFIQzfCLp2EaByyA8XgEUrP_2qkF70HQg01ZGyYcaOHaop77-W8u_qN-UetCnB4_q-nYPBEXuKkuNmkVtZN5us5ZgR9cO-fWwqMTfc_Jg=" rel="noreferrer noopener" target="_blank">marketing@theoncologyinstitute.com</a>



Investors



ICR Healthcare <a href="https://www.globenewswire.com/Tracker?data=IP6beJG18uZTvS1c6HVveNBqZivW8H8IKFVcvjofQzPYaKDIPycWTefUHQWyOz8-ElcjDrgoiwsak9kLpPO1eppu8cLR6dkxbdcMBW8WMz8aCcuHNDnSq0qCJCYl_KaHQcvfe0bJIfVHc7sA6J3GENJQ2fDZvKchpFWTFa65bFNedeL8nL7a9y-9byR6Zv7y3Zqwolzc5itNkqeqTyBA18PnZ3RA_lvL3mfazS4vlKg7-EK0O3m8kiFx1dNIZ2eE7-BFkp5psRNHepZkpTsYXi_sUqhMinFJ_D9_dlDp5eS3YO2VYQspCQsVRQ_D85cLqP8i33PcI0PtbU-8PiJI6xczQKJtSZATA57kueGd1tlqWF-GSRD4jRNaijxEdxYTbu2Jo8jgVqwAp9qye6VEL4VULXhQi0zjLr30fEszyaIBX6xk5TKIm0IlGwfTtArlPZoXo3ODPW2Lq7gJ7bPpOHuRdzn8N4LhMNuwD1I0NZjT6QUYpYDQfsnQaA_5aVOl" rel="noreferrer noopener" target="_blank">TOI@icrhealthcare.com</a>

Research News and Market Data on TOI



Jan 09, 2026



PDF Version



Rakesh Panda appointed Chief Information Officer



Nolan Mariano appointed Chief People Officer



CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) &#8212; The Oncology Institute, Inc. (NASDAQ: TOI) announced today the promotions of&nbsp;Rakesh Panda&nbsp;to Chief Information Officer and&nbsp;Nolan Mariano&nbsp;to Chief People Officer. These promotions reinforce TOI’s continued focus on leading the way in value-based cancer care through further development of our technology-enabled care delivery platform as well as strengthening our mission-oriented culture supported by strong leadership.



Rakesh Panda has more than 25 years of experience across IT, digital transformation, cybersecurity, and enterprise software development, including leadership roles at Cisco and Infosys. Mr. Panda will continue to guide TOI’s technology strategy, including AI-enablement efforts and enterprise-level data privacy and security practices. Nolan Mariano has 18 years of experience in People Operations and organizational leadership across several industries. Mr. Mariano joined TOI in 2022 and, as Chief People Officer, will oversee HR Operations, Total Rewards, Learning and Development, and Talent Acquisition functions.



Dr. Daniel Virnich, Chief Executive Officer at TOI, commented, “I&#8217;m extremely pleased to promote two strong internal leaders into key roles at TOI as we continue to experience rapid growth and new ways of driving world-class community-based cancer care for our patients and payor partners.”



About The Oncology Institute



Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.



Contacts



Media



The Oncology Institute, Inc.marketing@theoncologyinstitute.com



Investors



ICR HealthcareTOI@icrhealthcare.com

Release - The Oncology Institute Announces Leadership Promotions

Healthcare Services

The Oncology Institute

<figure class="wp-block-image aligncenter size-large"><img src="https://dashboard.channelchek.com/wp-content/uploads/2025/11/The-Beachbody-Company_Logo_RGB-1.svg" alt="" class="wp-image-98166"/></figure>



<a href="http://www.channelchek.com/company/bodi">Research News and Market Data on BODI </a>



January 8, 2026



EL SEGUNDO, Calif.--(BUSINESS WIRE)--&nbsp;The Beachbody Company, Inc. (NASDAQ: BODI) ("BODi" or the "Company"), a leading fitness and nutrition company, today announced it has entered into an amendment to its credit agreement with Tiger Finance, LLC, as administrative agent and collateral agent. This modification significantly enhances the Company's financial flexibility through amended covenant terms.



The amendment streamlines the financial covenant structure and adjusts certain financial covenants, including the number of digital subscriptions and total billings. The amended covenants, except for the amended liquidity covenant, will not be required to be tested if the Company’s cash balance is above a certain threshold.



The amendment continues to provide for potential interest rate reductions, with the first opportunity for rates to decrease now beginning with the period ended December 31, 2026.



Mark Goldston, Executive Chairman of BODi, commented: "These less restrictive covenants reflect our rapidly improving liquidity position and validate the strategic turnaround we've executed over the past two years. Our amended covenants provide us with additional flexibility to execute on our growth strategies as we transition from financial restructuring to capitalizing on new revenue opportunities in 2026."



Carl Daikeler, Co-Founder and Chief Executive Officer added: "This amendment positions us well to pursue our comprehensive retail initiative and innovation pipeline while maintaining the financial discipline that has delivered eight consecutive quarters of positive adjusted EBITDA."



The Company's cash position of $34 million on September 30, 2025, exceeded its $25 million debt level by $9 million. This strong financial position demonstrates the success of its financial transformation and positions BODi for its planned growth initiatives in 2026.



About BODi and The Beachbody Company, Inc.



BODi, formerly known as Beachbody, has been a pioneer in structured, step-by-step home fitness and nutrition programs for nearly three decades, with iconic programs like P90X, INSANITY, 21 Day Fix and the original premium superfood supplement, Shakeology. Since its inception, BODi has helped more than 30 million people reach life-changing results. Today, BODi continues to evolve with a simple mission: help people achieve their goals and lead healthy, fulfilling lives, especially busy, time-strapped people who want to fit healthy habits into everyday life with proven solutions. The BODi community empowers millions to stay motivated and accountable, supporting healthy weight management, improved metabolic function, increased mental and physical well-being, better sleep, as well as evidence-based habits that enhance healthspan and longevity.



For company and investor information, please visit&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fthebeachbodycompany.com%2Foverview%2Fdefault.aspx&amp;esheet=54391933&amp;newsitemid=20260108904888&amp;lan=en-US&amp;anchor=TheBeachbodyCompany.com&amp;index=1&amp;md5=64c91973635e8204c5c26491c0ae31e2">TheBeachbodyCompany.com</a>.



<figure class="wp-block-image"><img src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260108904888r1&amp;sid=q4-prod&amp;distro=nx&amp;lang=en" alt=""/></figure>



Investor Relations <a href="mailto:IR@BODi.com">IR@BODi.com</a>



Source: The Beachbody Company, Inc.

Research News and Market Data on BODI 



January 8, 2026



EL SEGUNDO, Calif.&#8211;(BUSINESS WIRE)&#8211;&nbsp;The Beachbody Company, Inc. (NASDAQ: BODI) (&#8220;BODi&#8221; or the &#8220;Company&#8221;), a leading fitness and nutrition company, today announced it has entered into an amendment to its credit agreement with Tiger Finance, LLC, as administrative agent and collateral agent. This modification significantly enhances the Company&#8217;s financial flexibility through amended covenant terms.



The amendment streamlines the financial covenant structure and adjusts certain financial covenants, including the number of digital subscriptions and total billings. The amended covenants, except for the amended liquidity covenant, will not be required to be tested if the Company’s cash balance is above a certain threshold.



The amendment continues to provide for potential interest rate reductions, with the first opportunity for rates to decrease now beginning with the period ended December 31, 2026.



Mark Goldston, Executive Chairman of BODi, commented: &#8220;These less restrictive covenants reflect our rapidly improving liquidity position and validate the strategic turnaround we&#8217;ve executed over the past two years. Our amended covenants provide us with additional flexibility to execute on our growth strategies as we transition from financial restructuring to capitalizing on new revenue opportunities in 2026.&#8221;



Carl Daikeler, Co-Founder and Chief Executive Officer added: &#8220;This amendment positions us well to pursue our comprehensive retail initiative and innovation pipeline while maintaining the financial discipline that has delivered eight consecutive quarters of positive adjusted EBITDA.&#8221;



The Company&#8217;s cash position of $34 million on September 30, 2025, exceeded its $25 million debt level by $9 million. This strong financial position demonstrates the success of its financial transformation and positions BODi for its planned growth initiatives in 2026.



About BODi and The Beachbody Company, Inc.



BODi, formerly known as Beachbody, has been a pioneer in structured, step-by-step home fitness and nutrition programs for nearly three decades, with iconic programs like P90X, INSANITY, 21 Day Fix and the original premium superfood supplement, Shakeology. Since its inception, BODi has helped more than 30 million people reach life-changing results. Today, BODi continues to evolve with a simple mission: help people achieve their goals and lead healthy, fulfilling lives, especially busy, time-strapped people who want to fit healthy habits into everyday life with proven solutions. The BODi community empowers millions to stay motivated and accountable, supporting healthy weight management, improved metabolic function, increased mental and physical well-being, better sleep, as well as evidence-based habits that enhance healthspan and longevity.



For company and investor information, please visit&nbsp;TheBeachbodyCompany.com.







Investor RelationsIR@BODi.com



Source: The Beachbody Company, Inc.

Release - BODi Announces Amendment to Credit Agreement

BODI

Media &amp; Entertainment

The Beachbody Company

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2021/01/eldn_logo.png" alt="" class="wp-image-68495" style="width:158px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/eldn">Research News and Market Data on ELDN </a>







January 8, 2026



<a href="https://ir.eledon.com/node/10976/pdf" target="_blank" rel="noreferrer noopener">PDF Version</a>



Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development



Reported positive preliminary results from first six patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study



Tegoprubart continues to be used as key component of immunosuppression regimen in xenotransplants, including three transplants of a genetically modified pig kidney into a human at&nbsp;Massachusetts General Hospital



Completed&nbsp;$57.5 million&nbsp;financing, with funds expected to support operations into 2Q 2027



IRVINE, Calif.,&nbsp;Jan. 08, 2026&nbsp;(GLOBE NEWSWIRE) --&nbsp;Eledon Pharmaceuticals, Inc.&nbsp;(“Eledon”) (Nasdaq: ELDN) today announced a summary of 2025 accomplishments and provided guidance for anticipated upcoming 2026 business milestones.



“2025 was a significant year for Eledon as we achieved multiple key milestones across our tegoprubart clinical programs in kidney allotransplantation, islet transplantation and xenotransplantation. We were particularly encouraged by results from our Phase 2 BESTOW trial, presented at ASN Kidney Week in November, which further validated the favorable safety and tolerability profile of tegoprubart, reducing the metabolic, neurologic and cardiovascular toxicities commonly associated with tacrolimus,” said&nbsp;David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “We look forward to engaging with regulatory authorities, including the FDA, as we advance tegoprubart into Phase 3 development this year, with the goal of delivering a safer alternative to tacrolimus-based immunosuppression. We also remain focused on expanding the potential of tegoprubart to address broader challenges such as organ shortages and type 1 diabetes and look forward to providing additional updates throughout the year.”



2025 Key Highlights



<ul class="wp-block-list">
<li>Presented results from the Phase 2 BESTOW clinical trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting in Houston, TX. Tegoprubart demonstrated a favorable safety and tolerability profile, reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus, the current standard of care in immunosuppression therapy. Kidney function, as measured by estimated glomerular filtration rate (eGFR), for study participants treated with tegoprubart was 69 mL/min/1.73 m² (n=51) at 12 months, delivering what the Company believes is the highest mean eGFR level reported to date in larger kidney transplant clinical trials evaluating rejection prevention. The efficacy failure composite endpoint including rejection rate was 22.2% in the tegoprubart group vs. 17.2% in the tacrolimus group demonstrating non-inferiority for tegoprubart vs. tacrolimus, using a 20% non-inferiority margin. The data support the advancement of tegoprubart into Phase 3 clinical development as a potential new standard immunosuppression approach for the prevention of organ rejection in patients undergoing kidney transplantation.</li>



<li>Reported positive preliminary results from the first six patients with type 1 diabetes (T1D) treated with tegoprubart as the core immunosuppressant following islet transplantation in an investigator-initiated trial conducted at the University of Chicago Medicine’s Transplant Institute. All six treated patients achieved insulin independence with marked improvements in glycemic control after one or two transplants, with the first three remaining insulin-free for more than one year after transplant. Results demonstrated prevention of islet rejection without calcineurin inhibitors (CNIs), such as tacrolimus, and sustained insulin-free HbA1c control. To date, a total of eight patients have undergone islet transplantation with tegoprubart as the core immunosuppressant, and one additional patient with CNI-associated nephrotoxicity was transitioned to tegoprubart from tacrolimus.</li>



<li>Announced the use of tegoprubart as a cornerstone component of the immunosuppression treatment regimen in a patient who received a xenotransplant of a genetically modified pig kidney, conducted at Massachusetts General Hospital (MGH) in collaboration with eGenesis. This procedure marked the fourth use of tegoprubart in a pig-to-human xenotransplant and the third use at MGH.</li>



<li>Completed a $57.5 million underwritten public offering of common stock and pre-funded warrants, which is anticipated to support company operations into the second quarter of 2027.</li>
</ul>



Anticipated 2026 Milestones



<ul class="wp-block-list">
<li>Present 24-month data from eight patients in Phase 1 extension study evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons (ASTS) Winter Symposium in Phoenix, AZ. Details are below: Title: Long-Term Outcomes of a Phase 1, Single Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen Abstract ID: #44 Session Title: Poster Session B Date: Friday, January 23, 2026, from 5:45 - 7:15 p.m. PT</li>
</ul>



<ul class="wp-block-list">
<li>Receive U.S. Food &amp; Drug Administration (“FDA”) guidance on the Phase 3 trial design assessing tegoprubart in kidney transplantation, followed by initiation of the Phase 3 trial pending regulatory alignment.</li>



<li>Report long-term data from the Phase 1 and Phase 2 BESTOW studies evaluating tegoprubart in kidney transplantation.</li>



<li>Report updated data from T1D patients in the investigator-led islet cell transplantation study evaluating tegoprubart at UChicago Medicine.</li>



<li>Receive FDA regulatory guidance on path to market for tegoprubart in islet cell transplantation and xenotransplantation.</li>



<li>Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients with renal dysfunction receiving an islet cell transplant.</li>



<li>Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients receiving a de novo liver transplant.</li>



<li>Initiate an investigator-led study evaluating tegoprubart for kidney transplant tolerance induction.</li>
</ul>



About&nbsp;Eledon Pharmaceuticals&nbsp;and tegoprubart



Eledon Pharmaceuticals, Inc.&nbsp;is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in&nbsp;Irvine,&nbsp;California. For more information, please visit the Company’s website at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=6Hpnf28_3mOcps-OzAb4lizwKgfbIr7HyuS_x1lyMdiqaP9FTGd8GjZ4Q02xpM0vRBZS-skZ28CsfCM2P2u4ic8WoZvnBc5kbzsjdDzyW09Wm7qSRwWdROLUF7HCOxrP8pRzQDn7kL2PO4ay84tmOozd4BOIXtlmo-EsQr8VdtoXBnEgFPnFDCKtr4pE4jexSVNLYYnwxSCmMHH7uN64dW9_ImPR-o1P27mYD9KckjE=" rel="noreferrer noopener" target="_blank">www.eledon.com</a>.



Follow&nbsp;Eledon Pharmaceuticals&nbsp;on social media:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=4GhhXAnlyqAcpY9wnqj55n-b1pptAS6s6QH1os5AMq-jrhYtc7B5EgzGeev6DnyaYY-MdoOOFaf9KH4PiLiH8-PEwT0P9T30f9s4ycioQX-HdKjQv3NOOc7o3QwJqxZA6xobcs9jAUFnmKrk_-85ma0JO2Y0HHqAuWrwOLIGAayDhsxP6ZWGpiGyKEswMJXzuayYH9Ft4TlrcZFtrvfsxJ7polR0eLSKlRAJ1G6WYpKDXWac8ohpXsTJD7wwT41vO1x5bt10Zdn3GroHyYLLHxdfTK9HsRpJT8ywHS5w_tyOFTsU4qWcEozLx1weFFSICl9ue7g1K1sBp8bwSy0rvPxTT_5KAxcF4BvmsMFy8NOg8-1-XJctjil-_cTP7HJ_oWADhc-xP7fTW1ex2boH3kK42PUIfvii1cC-M0BDm9m8vW1QD7ecMOFuXbxnl1hWW6KXxcwejsz2EA4OvlS0RLCDxt_rGNhuabz_SvzJ7gzsJVXL5rgnwj2PCalHvIcNbAVwucXdNKiZmnT3vS-9bXDq2KArjlzXkapHaYa4uUXMzFZaNJ0xMHmrP9a0zWElCdkuvuM9JJBXeY1tEpZVJCh9KvriY0r04W_TbjVjpmZ86z8NjOwjHmpbtpSsNhdCvGZnxj_SSOPtr4qmQPhKYw29Nk0WxURfjmQu5lCCE4DIkkbjZUvwHmrtKVoTMV1lyal3WomvCiIQJxJ6yd53JTrKpz0roxVmUUgkukWfVh-bPd2W5iWEeoSyUJ6zo3P08wTboDTAeJ2Bw4yz-6oYPAAzcabBM23uWVlL3wGM4Sj0i5MP0yf5kS5SkZC1h-bJl8uy1A3d8yAhHqsxGbF4iZlSbKQJT7kYZ79aG7saNpov-KTdV5q5o2uCAnH1Y-2W5zjfmNLZNIRlW3P4eQiKAhkgy8ND010yTjB1H67y-6QwCCXReheCDXT9L0cCk8_IveeAXTzP2pa9ctg-6fPbCkL20kUMEruMR-qk0u3iYvTuKo9_4eTqRv1rQyLzGqhC1wDunKohmB10iMDdVrfSp1pmlKqCVWAVAvVrIZ5NRqZoZeOAjq2735omBKEKHvorx1VaXtcSM3LnAdPSfSKq02Yk7LE2uXtdq15-R2Wd-__m2d0QJzxbGcREM5px_reNoYYfxm0OB-qVsrtz1FRPXvytX-vC7XUlmegE4Y50XPs18EcTN7lmf17DY4bCqhcSd4RGivf3GLmW3Qujn98G5qgW1CZJDrAMVpcUqm-sC6Qsoa21ecz92BmOXX6nMMavR56IXMJXOjs1WPi835oNSScuFdMpQP2a4BYl5gfr0UJgXdarRQrYYnR_Pm8JCQ63bTYlO_RnWTY3lL5iuDKYQ0HxA3NQRr1zIFRvjJC58PSip46gkvpSOQmQzDMSHC9vbM_IZuglzMUSlQOAC5ogKBVH08g3MC8zcs8SXrMvWOjvU-voNtPH1_b_EJEGp4NGZTz_JXoorTKXBhHEzoEGb9Yl9akKzbYSlYT4BmKcnqLYSLOzVUuQm6kQXKJHygNHBAwygynjLnwWIggdhDVUjqOy-zjZ5XuTGTg463-Y5a_FO-KiUogEoQDdvMQAkPZSaW2gm1qVh7G1Yk3pDgEAgKT0l9OsCc0CAWvLHO7Akdh_wUOjf6TFVeIahHL92KmGEZShwKP7FuDLfVyjmFdU8iepA3ZGMCb5kgjLmDtL2BoZGGPKAAY_zs13-xCeuUgMyPaKV5SPVAgTT2UI75E2kMHDmxwLsjPaCUypCz9lE_DoPME3tqoaKrRB6yRMtgVqeIAcUitsaoOnvTokDozmC-_7qRAD6qr1xlhRPiUKhUy7aH6awAAZMFuzkY-KUn9RAkeIaSnTeAumnOHqxw_1_W2Wq_NbIA5tjl_exhFYghOEMY1cy9JLXXqs-fzCx2QnZ75bsJWuiyyC13gxARKvd6Aqw9PVFOyLGQfguKLv0p-EcAaL2rM8SY88mtH7iwZHJIQbcV8tTUXQ8E9p0irEwztmACuS4PMic4HzG0x2kkWciJwrhiJWz0kV5UcHeTqZzMj300DhoHma7hwd0a2x-UcaJf0rXyrlMCJMwXnOiqBtp_BG4hAjy6b7E2jGV6VF_hLTs2cQvt4_H3WqSoYypA==" rel="noreferrer noopener" target="_blank">LinkedIn</a>;&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Ytno6p8tPCBjEI2XTJQGoy4tnXxLb6GPYVJbAtGmISeYDDvPAX4CZ-W2FBuDdrGXG9rm7KhF5Ynkz7i1AyaidRpuI6ddf7_eaBL034I1FlvA3T0L0UQ7ghQIhPogzd58pkXUa2o3gcBA1TwFrHjakuOQ4DE8xdQhwxKuyCJW5gAPl3bKtaWqvqidomwljlMq2rHcHmLvEGw5bcScWlhWLOXM2mpwFOSuD0CrLO_iHnpBRTRiBOa5eieKl3onlmiXa1cxwSn8gAm8-UHFAx6Inb7FC-JuXBc87pRWDZV9JiL1xOM5ZiMNDed9oGlbcNNP5jhsyJL4_GqAJaV9oWirVU7lxp4XvCThKggXI5Ieh-eyiSLfc2BSvdMt6YvxfPKBzB-LoWE1-y5h9lDdnAAaZagKgaGsC42xMDNywR8TubfxJ3ltmePllLLuZnFRhY1Iv8mhZhvGO7hWiNTVaT9zb5g31M4OZAtdxnIJhS5rtIVIGpen3Iu_pPgFtxavrxwt3cTOtReGiOPbszbEePwlNb06iQDMzcjynIr14jTR2Z139UARSsMdiRpdT1nR3LsDoSwE3NmrwQjfhUQiHBT_9V9qwY984h0tyKbAGkUYrLtDQ1yRrKWywmBlPQm9DAB010G9c2ywfaA7KrpFBBA-gn2IXKZxu-K--EsNItu-AvNqFoB9w0pd-SlPxux8laNzXbzaiAH9VuaKqz_eWlh6BDpIGOqoC5xZpAozgbGWoIo2E_vEQ6s8tMnL6QSQqNhF2n-1f7xuSUEYZBfgfPQpKx-rHobss5_5GS-pt_e7007LdxpCGxwHpQoSjDQqotKpI8kww21c0IVDCgTdygef2gsbCnwANC0qXF0vI6EO_k1IGmnNVieJpH9drd3obAQWbaSN9Bn8tJUQir4D5UdbAD8bQNnHoKuJaR8ovtmzCoXj9iuBKOdPCUjfnIbzQcIfufiLeC8n5tVaO6t1gLr48WwBh4U0vj3pktlQj8XKv675Z-O2S83l6FKvgi03OSDLKVGmYcezbdFjig6AnSi2rtRqnlAkb_2hRiA05F7Bfen506eXMDT2zs_VsxPSllchP-6j5sHDIMI4sJhva5fXQuOfAzUeUXj7EC_UMLyHXwlV00i-hGFWKojRg2uLvjN8FRQSwArPpXxaPdmtJDhXS4_jYF2SLXRqGlMtZfaImZ0fYE-GNIai_DEOdXl7JmutOo-Eb00WF4IxfEtasVlY-nZFYjKCwGGF8rmp3rvMhGqghiiqvq05SzG13pTZ_zVfdzKR6g5wFOP3wkPHnaQaCtugAAVbbUIuiFlUEkVNMRQxeQ5j7VW19ZLAEXHj-0xw3--7FdHR5-OyRqI44h72PNYoEBsQ8WWv0TS8xCHCQJqcfs2s0TvPvMqv-ZoDy6F8tx8kN_YKlBAXJbHCezLeIuUSjSNgA3ATlhHoySb9ujrIR-rQTDcW66s-Q8Hm-eXfMwIZGrHdR2X2_I2YmJ2SKjn-zqzwB167bk8-KJVZ-CQ2Wko7PWmqvImKO1XnA-SQ5bAzo_L29Z7E78yK7IW0v-_l77iQ5obRl6W-i5lTKkElXKZBbeO-iYdgj8J_Gtsnv4yZAazETEu8G7YQYmseO_MOUzzITV00rMpB-fN3iz_HetdpA7BNGQ8cwTSsVMIN6pyqVwiNcoGFwaQNv0ppg9vX3tvSgE48vIUWVzE3nN8vA1O5ose5XbE2RXf1yxn6_bZ9jGqpoFScsXtamJvdxeSAdysnsB78X5ypf0Gg0ka6ID_lHnvRz42TkZvCzV6qYUOeKe2S09s-DujeWLZBlwu8ZEb0kLmLV-ssn8WWb5sBbD72YF0Tv719pQol47SU4Fk3t2wNclqN7N5f2vfgziRXuunhyHrWuWirPva6IpPEw1r_zkYlPhZwSje_oxtKd77V0gThTrKBZ2LED9NgEdBM_-ttho0SNf417HZzPO6lwefawt7b1rLyTk-DSgB-MGl3zPRRaNr-eE_1c8faHp5B8TQZJ7WijaLf_zvN4-XrDmVdaZlxNq9KfB85s_NeuB-N9Z8gZUK9RJSR6ty5Tw==" rel="noreferrer noopener" target="_blank">Twitter</a>



Forward-Looking Statements



This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, the company’s capital resources and ability to finance planned clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to establish and maintain proper and effective internal control over financial reporting and other risks disclosed in our Quarterly Report on Form 10-Q for the quarter ended&nbsp;September 30, 2025, filed with the Securities and Exchange Commission on&nbsp;November 14, 2025. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at&nbsp;<a href="http://www.sec.gov/">www.sec.gov</a>. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.



Investor Contact:



Stephen Jasper Gilmartin Group (858) 525 2047 <a href="https://www.globenewswire.com/Tracker?data=zWXLTlk7Zj4jStoIPyO5gBnh26uosks0pdiu0XwTnAT2_ulyV5RgTf-zjsLxTAfo3249FgzADgZzu3WexAs-rlvLsHZBCbuOr4_oceCKUEn0DwwIxkEKJ6SCcm8KDxlf" rel="noreferrer noopener" target="_blank">stephen@gilmartinir.com</a>



Media Contact:



Jenna Urban CG Life (212) 253 8881 <a href="https://www.globenewswire.com/Tracker?data=S6BqgAdnPDsF76WO-G65Mn74-baHVEsiDahayq_qZmrGS3YLzXX8cAWMmKjzBCAodJGePyhDSU8jrl9bBrWNsr815-I1yzbiw5mEkE5C7Sw=" rel="noreferrer noopener" target="_blank">jurban@cglife.com</a>



Source:&nbsp;Eledon Pharmaceuticals<img alt="" src="https://www.globenewswire.com/newsroom/ti?nf=OTYyMjU2MiM3MzUyMTgyIzIwMDY1NTA="> <img alt="" src="https://ml.globenewswire.com/media/NGExNTM0ZmItMDgyMi00MTBmLWJmMTYtOTgzMGIzOTZiNjM5LTEwMTgxMjMtMjAyNi0wMS0wOC1lbg==/tiny/Eledon-Pharmaceuticals-Inc-.png">



<figure class="wp-block-image"><a class="external-link" href="https://www.globenewswire.com/NewsRoom/AttachmentNg/5e2f90ec-c9a5-4fcd-99c8-2c8c838ac033"><img src="https://ml.globenewswire.com/media/5e2f90ec-c9a5-4fcd-99c8-2c8c838ac033/small/eledon-logo-1230-png.png" alt="Primary Logo"/></a></figure>



Source: Eledon Pharmaceuticals, Inc.

Research News and Market Data on ELDN 







January 8, 2026



PDF Version



Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development



Reported positive preliminary results from first six patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study



Tegoprubart continues to be used as key component of immunosuppression regimen in xenotransplants, including three transplants of a genetically modified pig kidney into a human at&nbsp;Massachusetts General Hospital



Completed&nbsp;$57.5 million&nbsp;financing, with funds expected to support operations into 2Q 2027



IRVINE, Calif.,&nbsp;Jan. 08, 2026&nbsp;(GLOBE NEWSWIRE) &#8212;&nbsp;Eledon Pharmaceuticals, Inc.&nbsp;(“Eledon”) (Nasdaq: ELDN) today announced a summary of 2025 accomplishments and provided guidance for anticipated upcoming 2026 business milestones.



“2025 was a significant year for Eledon as we achieved multiple key milestones across our tegoprubart clinical programs in kidney allotransplantation, islet transplantation and xenotransplantation. We were particularly encouraged by results from our Phase 2 BESTOW trial, presented at ASN Kidney Week in November, which further validated the favorable safety and tolerability profile of tegoprubart, reducing the metabolic, neurologic and cardiovascular toxicities commonly associated with tacrolimus,” said&nbsp;David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “We look forward to engaging with regulatory authorities, including the FDA, as we advance tegoprubart into Phase 3 development this year, with the goal of delivering a safer alternative to tacrolimus-based immunosuppression. We also remain focused on expanding the potential of tegoprubart to address broader challenges such as organ shortages and type 1 diabetes and look forward to providing additional updates throughout the year.”



2025 Key Highlights




Presented results from the Phase 2 BESTOW clinical trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting in Houston, TX. Tegoprubart demonstrated a favorable safety and tolerability profile, reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus, the current standard of care in immunosuppression therapy. Kidney function, as measured by estimated glomerular filtration rate (eGFR), for study participants treated with tegoprubart was 69 mL/min/1.73 m² (n=51) at 12 months, delivering what the Company believes is the highest mean eGFR level reported to date in larger kidney transplant clinical trials evaluating rejection prevention. The efficacy failure composite endpoint including rejection rate was 22.2% in the tegoprubart group vs. 17.2% in the tacrolimus group demonstrating non-inferiority for tegoprubart vs. tacrolimus, using a 20% non-inferiority margin. The data support the advancement of tegoprubart into Phase 3 clinical development as a potential new standard immunosuppression approach for the prevention of organ rejection in patients undergoing kidney transplantation.



Reported positive preliminary results from the first six patients with type 1 diabetes (T1D) treated with tegoprubart as the core immunosuppressant following islet transplantation in an investigator-initiated trial conducted at the University of Chicago Medicine’s Transplant Institute. All six treated patients achieved insulin independence with marked improvements in glycemic control after one or two transplants, with the first three remaining insulin-free for more than one year after transplant. Results demonstrated prevention of islet rejection without calcineurin inhibitors (CNIs), such as tacrolimus, and sustained insulin-free HbA1c control. To date, a total of eight patients have undergone islet transplantation with tegoprubart as the core immunosuppressant, and one additional patient with CNI-associated nephrotoxicity was transitioned to tegoprubart from tacrolimus.



Announced the use of tegoprubart as a cornerstone component of the immunosuppression treatment regimen in a patient who received a xenotransplant of a genetically modified pig kidney, conducted at Massachusetts General Hospital (MGH) in collaboration with eGenesis. This procedure marked the fourth use of tegoprubart in a pig-to-human xenotransplant and the third use at MGH.



Completed a $57.5 million underwritten public offering of common stock and pre-funded warrants, which is anticipated to support company operations into the second quarter of 2027.




Anticipated 2026 Milestones




Present 24-month data from eight patients in Phase 1 extension study evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons (ASTS) Winter Symposium in Phoenix, AZ. Details are below:Title: Long-Term Outcomes of a Phase 1, Single Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression RegimenAbstract ID: #44Session Title: Poster Session BDate: Friday, January 23, 2026, from 5:45 &#8211; 7:15 p.m. PT





Receive U.S. Food &amp; Drug Administration (“FDA”) guidance on the Phase 3 trial design assessing tegoprubart in kidney transplantation, followed by initiation of the Phase 3 trial pending regulatory alignment.



Report long-term data from the Phase 1 and Phase 2 BESTOW studies evaluating tegoprubart in kidney transplantation.



Report updated data from T1D patients in the investigator-led islet cell transplantation study evaluating tegoprubart at UChicago Medicine.



Receive FDA regulatory guidance on path to market for tegoprubart in islet cell transplantation and xenotransplantation.



Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients with renal dysfunction receiving an islet cell transplant.



Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients receiving a de novo liver transplant.



Initiate an investigator-led study evaluating tegoprubart for kidney transplant tolerance induction.




About&nbsp;Eledon Pharmaceuticals&nbsp;and tegoprubart



Eledon Pharmaceuticals, Inc.&nbsp;is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in&nbsp;Irvine,&nbsp;California. For more information, please visit the Company’s website at&nbsp;www.eledon.com.



Follow&nbsp;Eledon Pharmaceuticals&nbsp;on social media:&nbsp;LinkedIn;&nbsp;Twitter



Forward-Looking Statements



This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, the company’s capital resources and ability to finance planned clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to establish and maintain proper and effective internal control over financial reporting and other risks disclosed in our Quarterly Report on Form 10-Q for the quarter ended&nbsp;September 30, 2025, filed with the Securities and Exchange Commission on&nbsp;November 14, 2025. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at&nbsp;www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.



Investor Contact:



Stephen JasperGilmartin Group(858) 525 2047stephen@gilmartinir.com



Media Contact:



Jenna UrbanCG Life(212) 253 8881jurban@cglife.com



Source:&nbsp;Eledon Pharmaceuticals







Source: Eledon Pharmaceuticals, Inc.

Release - Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Biotechnology

eldn

Eledon Pharmaceuticals

The final U.S. jobs report of 2025 delivered a sobering message: the labor market has slowed to a crawl. With just 50,000 jobs added in December, the year closed with the weakest pace of hiring outside of a recession in more than two decades. For investors—particularly those focused on small-cap stocks—this shift carries important implications as the economy enters 2026.



Total payroll growth for 2025 reached only 584,000 jobs, a dramatic fall from the roughly 2 million jobs added in 2024. Monthly gains averaged fewer than 50,000 positions, a level economists say is consistent with stagnation rather than expansion. While the unemployment rate dipped modestly to 4.4%, the decline was driven more by a shrinking labor force than by robust hiring.



Digging deeper, the data reveals a fragile employment landscape. Job creation was heavily concentrated in healthcare and social assistance, which together accounted for the majority of gains. Outside of those sectors, many industries experienced flat or negative hiring trends. Economists warn that future data revisions could show that overall employment actually contracted during parts of the year.



This environment has produced what many describe as a “no-hire, no-fire” economy. Companies are reluctant to lay off workers, but equally hesitant to expand payrolls amid higher borrowing costs, slower consumer demand, and lingering uncertainty around policy and global growth. For workers, this has translated into longer job searches and declining confidence. The share of unemployed individuals out of work for more than six months has risen sharply, signaling deeper structural weakness.



For investors, especially in the small-cap space, these conditions cut both ways. Slower job growth tends to pressure consumer spending, which can weigh on revenue for domestically focused companies. At the same time, a cooling labor market strengthens the case for interest rate relief later in 2026. If the Federal Reserve responds to weakening employment trends with rate cuts, smaller companies—often more sensitive to financing costs—could benefit disproportionately.



There are also early signs that the slowdown may be stabilizing. Layoff announcements declined in December, and private payroll data suggests hiring may be finding a floor. Some economists believe the worst of the labor market deceleration could already be behind us, setting the stage for a gradual recovery rather than a sharp downturn.



For small-cap investors, selectivity will be key. Businesses with strong balance sheets, pricing power, and exposure to resilient sectors may outperform if growth remains muted. Meanwhile, any meaningful improvement in hiring or labor participation could act as a catalyst for a broader re-rating across the small-cap universe.



As 2026 unfolds, the jobs market will remain a critical signal to watch. Whether this slowdown proves to be a pause—or a warning—will shape market sentiment, monetary policy, and investment opportunity in the months ahead.

The final U.S. jobs report of 2025 delivered a sobering message: the labor market has slowed to a crawl. With just 50,000 jobs added in December, the year closed with the weakest pace of hiring outside of a recession in more than two decades. For investors—particularly those focused on small-cap stocks—this shift carries important implications as the economy enters 2026.



Total payroll growth for 2025 reached only 584,000 jobs, a dramatic fall from the roughly 2 million jobs added in 2024. Monthly gains averaged fewer than 50,000 positions, a level economists say is consistent with stagnation rather than expansion. While the unemployment rate dipped modestly to 4.4%, the decline was driven more by a shrinking labor force than by robust hiring.



Digging deeper, the data reveals a fragile employment landscape. Job creation was heavily concentrated in healthcare and social assistance, which together accounted for the majority of gains. Outside of those sectors, many industries experienced flat or negative hiring trends. Economists warn that future data revisions could show that overall employment actually contracted during parts of the year.



This environment has produced what many describe as a “no-hire, no-fire” economy. Companies are reluctant to lay off workers, but equally hesitant to expand payrolls amid higher borrowing costs, slower consumer demand, and lingering uncertainty around policy and global growth. For workers, this has translated into longer job searches and declining confidence. The share of unemployed individuals out of work for more than six months has risen sharply, signaling deeper structural weakness.



For investors, especially in the small-cap space, these conditions cut both ways. Slower job growth tends to pressure consumer spending, which can weigh on revenue for domestically focused companies. At the same time, a cooling labor market strengthens the case for interest rate relief later in 2026. If the Federal Reserve responds to weakening employment trends with rate cuts, smaller companies—often more sensitive to financing costs—could benefit disproportionately.



There are also early signs that the slowdown may be stabilizing. Layoff announcements declined in December, and private payroll data suggests hiring may be finding a floor. Some economists believe the worst of the labor market deceleration could already be behind us, setting the stage for a gradual recovery rather than a sharp downturn.



For small-cap investors, selectivity will be key. Businesses with strong balance sheets, pricing power, and exposure to resilient sectors may outperform if growth remains muted. Meanwhile, any meaningful improvement in hiring or labor participation could act as a catalyst for a broader re-rating across the small-cap universe.



As 2026 unfolds, the jobs market will remain a critical signal to watch. Whether this slowdown proves to be a pause—or a warning—will shape market sentiment, monetary policy, and investment opportunity in the months ahead.

America’s Hiring Stall: What the Weak Jobs Market Means for Investors in 2026

Economy

Jobs

Labor Market

Unemployment

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Friday, January 09, 2026



Resources Connection, Inc. provides agile consulting services in North America, Europe, and the Asia Pacific. The company offers finance and accounting services, including process transformation and optimization, financial reporting and analysis, technical and operational accounting, merger and acquisition due diligence and integration, audit readiness, preparation and response, implementation of new accounting standards, and remediation support. It also provides information management services, such as program and project management, business and technology integration, data strategy, and business performance management. In addition, the company offers corporate advisory, strategic communications, and restructuring services; and corporate governance, risk, and compliance management services, such as contract and regulatory compliance, enterprise risk management, internal controls management, and operation and information technology (IT) audits. Further, it provides supply chain management services comprising strategy development, procurement and supplier management, logistics and materials management, supply chain planning and forecasting, and unique device identification compliance; and human capital services, including change management, organization development and effectiveness, compensation and incentive plan strategies, and optimization of human resources technology and operations. Additionally, the company offers legal and regulatory supporting services for commercial transactions, global compliance initiatives, law department operations, and law department business strategies and analytics. It also provides policyIQ, a proprietary cloud-based governance, risk, and compliance software application. The company was formerly known as RC Transaction Corp. and changed its name to Resources Connection, Inc. in August 2000. Resources Connection, Inc. was founded in 1996 and is headquartered in Irvine, California.



Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.



Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Continued Revenue Pressure.&nbsp;RGP reported second quarter revenue of $117.7 million, down 19% year-over-year. On a same-day constant currency basis, revenue declined 18.4%, driven almost entirely by lower billable hours across the core On-Demand and Consulting segments. Importantly, the weakness remains volume-driven rather than price-driven, as average bill rates were largely stable and improved in several key geographies.



Pricing Discipline, Volume Weak.&nbsp;The Company continues to make progress with its value-based pricing initiatives. U.S. bill rates increased 2.5% year over year, Consulting bill rates rose 6.6%, and On-Demand bill rates increased 2.6%. However, these gains were more than offset by sharp declines in billable hours, particularly in Consulting (-33.8%) and On-Demand (-21.5%). Management specifically highlighted reduced demand for traditional finance roles as clients adopt automation and AI, underscoring that part of the On-Demand softness may be structural rather than purely cyclical.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/27987">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Friday, January 09, 2026



Resources Connection, Inc. provides agile consulting services in North America, Europe, and the Asia Pacific. The company offers finance and accounting services, including process transformation and optimization, financial reporting and analysis, technical and operational accounting, merger and acquisition due diligence and integration, audit readiness, preparation and response, implementation of new accounting standards, and remediation support. It also provides information management services, such as program and project management, business and technology integration, data strategy, and business performance management. In addition, the company offers corporate advisory, strategic communications, and restructuring services; and corporate governance, risk, and compliance management services, such as contract and regulatory compliance, enterprise risk management, internal controls management, and operation and information technology (IT) audits. Further, it provides supply chain management services comprising strategy development, procurement and supplier management, logistics and materials management, supply chain planning and forecasting, and unique device identification compliance; and human capital services, including change management, organization development and effectiveness, compensation and incentive plan strategies, and optimization of human resources technology and operations. Additionally, the company offers legal and regulatory supporting services for commercial transactions, global compliance initiatives, law department operations, and law department business strategies and analytics. It also provides policyIQ, a proprietary cloud-based governance, risk, and compliance software application. The company was formerly known as RC Transaction Corp. and changed its name to Resources Connection, Inc. in August 2000. Resources Connection, Inc. was founded in 1996 and is headquartered in Irvine, California.



Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.



Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Continued Revenue Pressure.&nbsp;RGP reported second quarter revenue of $117.7 million, down 19% year-over-year. On a same-day constant currency basis, revenue declined 18.4%, driven almost entirely by lower billable hours across the core On-Demand and Consulting segments. Importantly, the weakness remains volume-driven rather than price-driven, as average bill rates were largely stable and improved in several key geographies.



Pricing Discipline, Volume Weak.&nbsp;The Company continues to make progress with its value-based pricing initiatives. U.S. bill rates increased 2.5% year over year, Consulting bill rates rose 6.6%, and On-Demand bill rates increased 2.6%. However, these gains were more than offset by sharp declines in billable hours, particularly in Consulting (-33.8%) and On-Demand (-21.5%). Management specifically highlighted reduced demand for traditional finance roles as clients adopt automation and AI, underscoring that part of the On-Demand softness may be structural rather than purely cyclical.



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Resources Connection (RGP) - Pricing Discipline Holds as Volume Pressure Persists

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Friday, January 09, 2026



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Direct Digital remained a key strategic channel, supporting customer acquisition, margin mix improvement, and first-party data ownership despite a challenging macro and media cost environment. The channel continued to evolve toward a full-funnel model, with increasing contribution from returning customers, improved conversion rates, and greater emphasis on retention and lifecycle engagement.



Repositioning for strategic growth.&nbsp;Ongoing headwinds from media cost inflation, intensifying competition, and platform volatility have persisted in 2025, prompting a strategic shift toward owned-channel development, tighter audience targeting, and stronger cross-functional execution. Looking forward, Direct Digital is increasingly aligned around a more disciplined growth model, prioritizing customer retention, lifetime value, and earnings durability over volume-driven top-line expansion.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/27952">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Friday, January 09, 2026



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Direct Digital remained a key strategic channel, supporting customer acquisition, margin mix improvement, and first-party data ownership despite a challenging macro and media cost environment. The channel continued to evolve toward a full-funnel model, with increasing contribution from returning customers, improved conversion rates, and greater emphasis on retention and lifecycle engagement.



Repositioning for strategic growth.&nbsp;Ongoing headwinds from media cost inflation, intensifying competition, and platform volatility have persisted in 2025, prompting a strategic shift toward owned-channel development, tighter audience targeting, and stronger cross-functional execution. Looking forward, Direct Digital is increasingly aligned around a more disciplined growth model, prioritizing customer retention, lifetime value, and earnings durability over volume-driven top-line expansion.



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Direct Digital Holdings (DRCT) - Year End Review: 2026 Could Be A Pivotal Year

Direct Digital Holdings

DRCT

Media

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Friday, January 09, 2026



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



FY 2026 third-quarter financial results.&nbsp;AZZ reported adjusted net income of $46.0 million, or $1.52 per share, compared to $41.9 million, or $1.39 per share, during the prior year period. We had forecast adjusted net income of $44.9 million, or $1.48 per share. Compared to the third quarter of FY 2025, total sales increased 5.5% to $425.7 million. We had projected sales of $424.6 million. Gross margin of $101.9 million was modestly below our estimate of $103.2 million. Operating income of $69.5 million exceeded our estimate of $64.9 million, due to lower selling, general, and administrative expenses. Adjusted EBITDA increased modestly to $91.2 million compared to $90.7 million during the prior year period and our estimate of $93.3 million.



Updating estimates.&nbsp;With one quarter remaining, we have lowered our FY 2026 EBITDA estimate to $368.0 million from $369.2 million, and increased our EPS estimate to $6.03 from $5.98. We have increased our 2027 EBITDA and EPS estimates to $388.0 million and $6.60, respectively, from $387.4 million and $6.45.&nbsp;Our longer-term estimates through FY 2031 reflect multi-year growth and are summarized at the end of this report. Our estimates do not reflect the impact of acquisitions until announced.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/27989">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Friday, January 09, 2026



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



FY 2026 third-quarter financial results.&nbsp;AZZ reported adjusted net income of $46.0 million, or $1.52 per share, compared to $41.9 million, or $1.39 per share, during the prior year period. We had forecast adjusted net income of $44.9 million, or $1.48 per share. Compared to the third quarter of FY 2025, total sales increased 5.5% to $425.7 million. We had projected sales of $424.6 million. Gross margin of $101.9 million was modestly below our estimate of $103.2 million. Operating income of $69.5 million exceeded our estimate of $64.9 million, due to lower selling, general, and administrative expenses. Adjusted EBITDA increased modestly to $91.2 million compared to $90.7 million during the prior year period and our estimate of $93.3 million.



Updating estimates.&nbsp;With one quarter remaining, we have lowered our FY 2026 EBITDA estimate to $368.0 million from $369.2 million, and increased our EPS estimate to $6.03 from $5.98. We have increased our 2027 EBITDA and EPS estimates to $388.0 million and $6.60, respectively, from $387.4 million and $6.45.&nbsp;Our longer-term estimates through FY 2031 reflect multi-year growth and are summarized at the end of this report. Our estimates do not reflect the impact of acquisitions until announced.



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

AZZ (AZZ) - Third Quarter FY26 Review and Outlook

Noble Capital Markets Research Morning Call

The artificial intelligence boom is no longer just about software models and chips—it’s increasingly about power, land, and infrastructure. That reality came into sharp focus this week as OpenAI and SoftBank jointly committed $1 billion to SB Energy, a fast-growing energy and data center infrastructure company positioned at the center of America’s AI buildout.



Under the deal, OpenAI and SoftBank will each invest $500 million to support SB Energy’s expansion as a large-scale developer and operator of data centers. As part of the partnership, SB Energy has been selected to build and operate OpenAI’s 1.2-gigawatt data center in Milam County, Texas, a facility large enough to power hundreds of thousands of homes. The investment highlights a critical shift: for AI leaders, securing reliable energy has become as strategic as securing advanced chips.



AI workloads are extraordinarily power-hungry. Training and running large language models requires enormous computing capacity, which in turn drives unprecedented electricity demand. As a result, hyperscalers and AI developers are now racing to lock down long-term energy sources and infrastructure partners to avoid future bottlenecks. In this environment, companies that can deliver power at scale are emerging as essential enablers of the AI economy.



SB Energy represents a hybrid model well-suited for this moment. Originally founded as a renewable energy and storage developer and long backed by SoftBank, the company has expanded aggressively into data center development, ownership, and operations. This dual exposure to both energy production and digital infrastructure positions SB Energy as a critical middle layer between power generation and AI compute demand.



The investment also ties directly into OpenAI’s Stargate initiative, a massive joint effort with partners including SoftBank and Oracle to invest up to $500 billion in U.S. AI infrastructure over the next four years. Stargate’s ambition underscores how central physical infrastructure has become to sustaining AI growth—and why capital is flowing into companies that can execute at scale.



From an investor’s perspective, this trend carries important implications. While mega-cap tech companies dominate AI headlines, much of the real opportunity may lie one layer below, in infrastructure providers, energy developers, and specialized operators that enable AI expansion. These businesses often generate long-term contracted revenue and may benefit from structural demand regardless of short-term swings in AI sentiment.



However, the rapid interconnection between AI firms, financiers, and infrastructure developers also introduces risk. Heavy capital commitments assume that AI demand will continue to rise at an aggressive pace. If adoption slows or efficiency gains reduce power needs, some projects could face pressure. Investors should therefore favor companies with diversified customers, strong balance sheets, and assets that retain value beyond AI-specific use cases.



Ultimately, the OpenAI–SoftBank investment in SB Energy signals a broader shift: AI is becoming an infrastructure-driven industry. For investors willing to look beyond the obvious names, the companies powering the AI revolution—literally—may offer some of the most compelling opportunities in the years ahead.

The artificial intelligence boom is no longer just about software models and chips—it’s increasingly about power, land, and infrastructure. That reality came into sharp focus this week as OpenAI and SoftBank jointly committed $1 billion to SB Energy, a fast-growing energy and data center infrastructure company positioned at the center of America’s AI buildout.



Under the deal, OpenAI and SoftBank will each invest $500 million to support SB Energy’s expansion as a large-scale developer and operator of data centers. As part of the partnership, SB Energy has been selected to build and operate OpenAI’s 1.2-gigawatt data center in Milam County, Texas, a facility large enough to power hundreds of thousands of homes. The investment highlights a critical shift: for AI leaders, securing reliable energy has become as strategic as securing advanced chips.



AI workloads are extraordinarily power-hungry. Training and running large language models requires enormous computing capacity, which in turn drives unprecedented electricity demand. As a result, hyperscalers and AI developers are now racing to lock down long-term energy sources and infrastructure partners to avoid future bottlenecks. In this environment, companies that can deliver power at scale are emerging as essential enablers of the AI economy.



SB Energy represents a hybrid model well-suited for this moment. Originally founded as a renewable energy and storage developer and long backed by SoftBank, the company has expanded aggressively into data center development, ownership, and operations. This dual exposure to both energy production and digital infrastructure positions SB Energy as a critical middle layer between power generation and AI compute demand.



The investment also ties directly into OpenAI’s Stargate initiative, a massive joint effort with partners including SoftBank and Oracle to invest up to $500 billion in U.S. AI infrastructure over the next four years. Stargate’s ambition underscores how central physical infrastructure has become to sustaining AI growth—and why capital is flowing into companies that can execute at scale.



From an investor’s perspective, this trend carries important implications. While mega-cap tech companies dominate AI headlines, much of the real opportunity may lie one layer below, in infrastructure providers, energy developers, and specialized operators that enable AI expansion. These businesses often generate long-term contracted revenue and may benefit from structural demand regardless of short-term swings in AI sentiment.



However, the rapid interconnection between AI firms, financiers, and infrastructure developers also introduces risk. Heavy capital commitments assume that AI demand will continue to rise at an aggressive pace. If adoption slows or efficiency gains reduce power needs, some projects could face pressure. Investors should therefore favor companies with diversified customers, strong balance sheets, and assets that retain value beyond AI-specific use cases.



Ultimately, the OpenAI–SoftBank investment in SB Energy signals a broader shift: AI is becoming an infrastructure-driven industry. For investors willing to look beyond the obvious names, the companies powering the AI revolution—literally—may offer some of the most compelling opportunities in the years ahead.

The Real AI Arms Race: Why Power and Data Centers Are Becoming the Next Big Investment Theme

Data centers

Energy

Open AI

Footer menu

Contact Me

Feedback

Test form

Event Registration

The NobleCon20 VIP Giveaway

Noble Announcement | 2H 2025 Events

Main menu

The NobleCon20 VIP Giveaway – Terms and Conditions
1. Organizer The NobleCon20 VIP Giveaway (“Contest”) is organized by Noble Financial Group and Channelchek (“Organizers”).
2. Eligibility The Contest is open to legal residents of the United States who are 18 years of age or older at the time of entry. Employees of the Organizers, their affiliates, subsidiaries, advertising and promotion agencies, and immediate family members are not eligible to participate.
3. Contest Period The Contest begins on [Start Date] and ends on October 31, 2024, at 11:59 PM ET. Entries submitted after the Contest Period will not be considered.
4. How to Enter To enter the Contest:
<ul>
<li>You must be a registered and verified Channelchek member.</li>
<li>You must complete the Contest entry form available at [Entry Form URL].</li>
</ul>
5. Prize The prize package includes:
<ul>
<li>Round-trip economy airfare for two (2) to South Florida to attend NobleCon20.</li>
<li>Two (2) hotel rooms for the duration of NobleCon20.</li>
<li>Two (2) tickets to NobleCon20, including access to all official NobleCon20 events.</li>
<li>Two (2) VIP meet-and-greet upgrades to the headline event featuring three (3) of the Sharks from ABC’s Shark Tank.</li>
</ul>
There will be one (1) winner chosen. All travel and accommodations are subject to availability and must be arranged through the Organizers. No substitution, transfer, or cash equivalent of prizes is permitted.
6. Winner Selection The winner will be selected on November 1, 2024. The winner will be notified via email using the contact information provided during entry. If the winner does not respond within seven (7) days of the notification, the Organizers reserve the right to select an alternate winner.
7. General Conditions
<ul>
<li>No purchase is necessary to enter or win.</li>
<li>The Contest is void where prohibited by law.</li>
<li>The prize does not include a presentation slot at NobleCon20.</li>
<li>By participating, entrants agree to be bound by these Terms and Conditions and the decisions of the Organizers, which are final and binding in all respects.</li>
<li>The Organizers reserve the right to disqualify any entry that is incomplete, misdirected, or in violation of these Terms and Conditions.</li>
</ul>
8. Privacy By entering the Contest, you agree that your personal information may be used by the Organizers in accordance with their privacy policies.
9. Limitation of Liability The Organizers are not responsible for any incorrect or inaccurate information, technical failures, or unauthorized intervention in the Contest. The Organizers are not liable for any injury or damage to persons or property resulting from participation in the Contest or acceptance or use of any prize.
10. Contact Information For questions or further information about the Contest, please contact the Organizers at contact@channelchek.com.

NobleCon20 VIP Contest Terms

NobleCon20 VIP Giveaway

Show form on click button

<h3 style="text-align: center;">Enjoying Channelchek?</h3>
There&#8217;s more to explore!
<a href="https://www.channelchek.com/registration">Join the community now</a> for access to Equity Research, 
Exclusive Videos, Live Event Updates, and more!
It&#8217;s absolutely free to join.
<a href="https://www.channelchek.com/registration"><img loading="lazy" decoding="async" class=" wp-image-64177 aligncenter" src="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg" alt="" width="351" height="301" srcset="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg 300w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-1024x876.jpg 1024w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-768x657.jpg 768w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-1536x1314.jpg 1536w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-2048x1752.jpg 2048w" sizes="auto, (max-width: 351px) 100vw, 351px" /></a>
<script id="xverse-wallet-provider" src="chrome-extension://idnnbdplmphpflfnlkomgpfbpcgelopg/inpage.js"></script>